Company: BDRX
Filing Date: 2025-09-26
Form Type: F-3
Source: 0001214659-25-014255
Chunk: 94

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-26
Form: F-3
Chunk 94
---
ominated 
 and the currency or units in which principal or interest or both will or may be payable;                         |

| · | whether we will issue the series of debt securities in global form, the terms of any global securities 
 and who the depositary will be;                                                                        |

| · | the maturity date and the date or dates on which principal will be payable; |

| · | the interest rate, which may be fixed or variable, or the method for determining the rate and the date                                  
 interest will begin to accrue, the date or dates interest will be payable and the record dates for interest payment dates or the method 
 for determining such dates;                                                                                                             |

| · | whether or not the debt securities will be secured or unsecured, and the terms of any secured debt; |

| · | the terms of the subordination of any series of subordinated debt; |

| · | the place or places where payments will be payable; |

| · | our right, if any, to defer payment of interest and the maximum length of any such deferral period; |

| · | the date, if any, after which, and the price at which, we may, at our option, redeem the series of debt 
 securities pursuant to any optional redemption provisions;                                              |

| · | the date, if any, on which, and the price at which we are obligated, pursuant to any mandatory sinking         
 fund provisions or otherwise, to redeem, or at the holder’s option to purchase, the series of debt securities; |

| 52 |

| · | whether the indenture will restrict our ability to pay dividends, or will require us to maintain any asset 
 ratios or reserves;                                                                                        |

| · | whether we will be restricted from incurring any additional indebtedness; |

| · | a discussion of any material or special U.S. federal income tax considerations applicable to a series 
 of debt securities;                                                                                   |

| · | the denominations in which we will issue the series of debt securities, if other than denominations of 
 $1,000 and any integral multiple thereof; and                                                          |

| · | any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities.                                
 We may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration   
 of acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the federal income tax 
 considerations and other special considerations applicable to any of these debt